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Central nervous system pathology
in preclinical MPS IIIB dogs reveals
progressive changes in clinically
relevant brain regions
Martin T. Egeland1,6, Marta M. Tarczyluk‑Wells2,6, Melissa M. Asmar2, Evan G. Adintori3,
Roger Lawrence3, Elizabeth M. Snella4, Jackie K. Jens4, Brett E. Crawford3, Jill C. M. Wait3,
Emma McCullagh3, Jason Pinkstaff3, Jonathan D. Cooper1,2,5* & N. Matthew Ellinwood4
Mucopolysaccharidosis type IIIB (MPS IIIB; Sanfilippo syndrome B) is an autosomal recessive
lysosomal storage disorder caused by the deficiency of alpha-N-acetylglucosaminidase activity,
leading to increased levels of nondegraded heparan sulfate (HS). A mouse model has been useful
to evaluate novel treatments for MPS IIIB, but has limitations. In this study, we evaluated the
naturally occurring canine model of MPS IIIB for the onset and progression of biochemical and
neuropathological changes during the preclinical stages (onset approximately 24–30 months of age)
of canine MPS IIIB disease. Even by 1 month of age, MPS IIIB dogs had elevated HS levels in brain and
cerebrospinal fluid. Analysis of histopathology of several disease-relevant regions of the forebrain
demonstrated progressive lysosomal storage and microglial activation despite a lack of cerebrocortical
atrophy in the oldest animals studied. More pronounced histopathology changes were detected in
the cerebellum, where progressive lysosomal storage, astrocytosis and microglial activation were
observed. Microglial activation was particularly prominent in cerebellar white matter and within the
deep cerebellar nuclei, where neuron loss also occurred. The findings in this study will form the basis of
future assessments of therapeutic efficacy in this large animal disease model.
Abbreviations
CNS	Central nervous system
CSF	Cerebrospinal fluid
DCN	Deep cerebellar nuclei
ERT	Enzyme replacement therapy
GAG	Glycosaminoglycan
GFAP	Glial fibrillary associated protein
HS	Heparan sulfate
HS-NRE	Non-reducing end of HS
Iba1	Ionized calcium binding adaptor molecule 1
LAMP1	Lysosomal membrane protein 1
LSD	Lysosomal storage disorder
MPS	Mucopolysaccharidosis
NAGLU	Alpha-N-acetylglucosaminidase
SEM	Standard error of mean
TBS	Tris-buffered saline
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Mucopolysaccharidosis type III (MPS III—Sanfilippo syndrome) is a group of autosomal recessive lysosomal
storage disorders (LSDs), each caused by a specific enzymatic deficiency in the catabolic pathway of the glycosaminoglycan (GAG), heparan sulfate (HS)1. GAGs including HS are normally degraded by step-wise enzymatic
modification removal of terminal sugars and sulfates at the non-reducing ends of GAG chains2.Therefore, individual deficiency in the enzymes involved in these catabolic pathways results in the lysosomal storage of nondegraded GAGs. Mucopolysaccharidosis type III is a heterogeneous condition comprised of four disorders in
humans, MPS IIIA–IIID (OMIM 252900, 252920, 252930, and 252940). Each MPS III subtype is characterized
by mutations in one of four distinct enzymes, each with an obligate and non-redundant role in HS catabolism.
Deficiencies in the activities of each of these enzymes result in the accumulation of a disease-specific HS moiety
at the non-reducing end (HS-NRE)2. Unlike most MPS disorders, MPS III patients have severe central nervous
system (CNS) symptoms with relatively few peripheral disease manifestations.
MPS IIIB accounts for approximately 30% of all MPS III cases and is caused by mutations in the NAGLU gene,
which encodes the enzyme alpha-N-acetylglucosaminidase (NAGLU; EC 3.2.1.50)3–5. Patients appear normal at
birth but present with early developmental delays followed by severe behavioural abnormalities and progressive
neurodegeneration. Patients typically succumb to their disease in their mid-teens1.
There is currently no approved treatment for MPS IIIB that targets the underlying disease. The challenge of
developing effective therapies can be aided by the characterization of animal models that recapitulate important
aspects of the human disease. A NAGLU deficient mouse (MPS IIIB mouse) model has been generated6, which
display increased levels of HS and the MPS IIIB-specific HS-NRE in brain t issue7, 8, and neuropathological findings similar to those described in the human disease, including increased microgliosis and astrocytosis in the
brain9. Treatment of MPS IIIB mice with recombinant human NAGLU (rhNAGLU) or AAV9-murine Naglu
resolved biochemical, pathological and behavioural manifestations of murine MPS I IIB7,10,11 .
Despite such advances in MPS IIIB mice, small animal models are limited by a relative lack of neurological
complexity and differences in physiological dynamics, making assessments of potential treatments for human
use difficult. Larger animal models can provide additional, complementary disease pathology information and
are well-suited for confirming the safety and pharmacologic activity of potential therapeutics before initiation of
human testing. These models better represent the human disease and response to therapy because of the greater
genetic similarity to humans, outbred status, robust immune system, greater size (including brain size and
complexity), and longer lifespan. Large animal models of the MPS disorders have long been a productive focus
of preclinical research in these disorders12. Specifically, large animal models of MPS IIIB have been described in
emus13, cattle14, swine15, and canines, but only the canine model exists in a research setting suitable to evaluate
a preclinical therapy16. A canine model of MPS IIIB has been described in the schipperke breed. Two dogs with
naturally occurring MPS IIIB were found to have physical signs of and adult onset at approximately three years
of age, of cerebellar disease including ataxia and t remor17. Gross pathological analysis of these dogs at 4.2 and
5.6 years of age revealed atrophy of the cerebellum with Purkinje cell loss, neuronal cytoplasmic vacuolation/
granulation, and microglial vacuolation throughout the CNS, with somatic disease restricted chiefly to liver,
kidney and tissue resident macrophages throughout the body17. The molecular defect in the canine NAGLU locus
is involves the insertion of approximately 45 A residues flanked by an 11 base pair duplication of native sequence
5′ to the insertion16 in the last exon of the gene. Hence, while the initial clinical and molecular characterization
has occurred, a longitudinal biochemical and histopathological assessment of the CNS disease in the current
outbred colony of MPS IIIB dogs has not yet been conducted.
In this study, we describe the onset and progression of biochemical and neuropathological changes in the
CNS of MPS IIIB dogs and unaffected control dogs at different ages during development up to 20 months of age,
before the time point when these dogs develop clear motor signs. The biochemical characterization of the kinetics
of substrate accumulation focused on the cortical grey matter and the cerebrospinal fluid (CSF). Histopathological analyses centred on the cerebellum as a known area of disease pathology. Other brain regions associated
with the symptomatology of human MPS IIIB were also examined including the hippocampus, thalamus, and
hypothalamus. In addition to obtaining baseline natural history data to document progressive biochemical and
neuropathological changes in preclinical MPS IIIB dogs, our goal was to determine measures that could inform
therapeutic benefit of potential future treatments for MPS IIIB disease.

Results

The accumulation over time of non-degraded HS polysaccharide and oligosaccharide chains was quantified in
MPS IIIB dogs at 1, 2, 3, 6, 9, and 12 months of age. Total HS, as defined by the sum of the internal disaccharides
of HS, and the MPS IIIB-specific non-reducing end of HS (the substrate of NAGLU enzymatic activity) were
measured in brain tissue (cerebral grey matter), CSF, plasma, and urine (Fig. 1, Supplementary Figure 1, Individual dog IDs presented in Table 1). Unaffected dogs had low levels of HS and HS-NRE in brain tissue, CSF,
plasma, and urine at all time points tested (Fig. 1, Supplementary Figure 1). In contrast, levels of total HS and
HS-NRE in brain, CSF, plasma and urine of MPS IIIB dogs were markedly increased over levels in unaffected
dogs (Fig. 1, Supplementary Figure 1). In the cortex of MPS IIIB dogs, high levels of HS and HS-NRE were
detected at 1 month of age (the earliest time point tested), and levels of total HS increased over time and began
to plateau by about 12 months of age (Fig. 1A). In the CSF of MPS IIIB dogs, levels of total HS and HS-NRE
decreased over time, reaching a steady state of approximately 17-fold over levels in unaffected dogs by approximately 6 months of age (Fig. 1B).
Increased sulfation of HS occurs in mouse models of MPS IIIB and other MPS d
 isorders18. To assess whether
the composition of the HS changes over time in MPS IIIB dogs, we quantified the extent of the distinct sulfation
modifications (2-O, 6-O, and N-sulfation) as well as the abundance of N-acetylated glucosamine. We found
that the abundance of 2-O sulfated and N-sulfated HS subtly increased while the abundance of N-acetylated HS
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Figure 1.  Increased levels of heparan sulfate (HS) and the MPS IIIB-specific non-reducing end of HS
(HS-NRE) in brain and cerebrospinal fluid (CSF) of MPS IIIB dogs compared to unaffected dogs. LCMS
quantification of HS levels (top row) and HS-NRE (bottom row) in homogenized cerebral grey matter (A) and
CSF (B) from MPS IIIB (circles, grey bars) and unaffected dogs (triangles, empty bars) at different ages from
1 to 12 months old. Levels in cerebral grey matter were normalized to wet brain mass. Bars illustrate the mean
(horizontal line) and standard deviation of data for time points at which samples from more than two dogs
were analyzed. Data points with a horizontal line through them but no bar represent more than one sample was
analyzed but the variability was extremely small. Data points with no horizontal line indicate a sample from a
single animal was analyzed. See Supplementary Table 1 for raw data.
subtly decreased over time in brain tissue of MPS IIIB dogs (Supplementary Figure 2A). The composition of HS
in CSF remained consistent over the time period measured (Supplementary Figure 2B). In summary, MPS IIIB
dogs have high levels of HS and HS-NRE in several tissues including brain and CSF. These levels are consistently
higher in MPS IIIB dogs than unaffected dogs, even at 1 month of age, the earliest time point evaluated. These
results demonstrate a way to directly measure the accumulation of NAGLU substrates (HS and HS-NRE) by
LCMS in the brain and in fluids which is easily monitored in the clinic (CSF, plasma, and urine) and provides a
tool to measure the primary biochemical activity of NAGLU and its correction with therapy.

MPS IIIB disease forebrain pathology

To understand the effects of HS accumulation on brain pathology, changes in brain architecture were evaluated
by histology.

Increased lysosomal storage in the forebrain of MPS IIIB dogs. Lysosomal membrane protein-1

(LAMP1) has been used as a surrogate marker of lysosomal storage burden and has been shown to indicate the
size of the lysosomal compartment, despite only being a proxy measure10. Tissue from the forebrain of MPS IIIB
dogs 15 months of age showed increased LAMP1 staining over the corresponding unaffected controls (Fig. 2).
Due to the diffuse background staining within the neuropil of the oldest available MPS IIIB dogs (data not
shown), increased LAMP1 staining was most evident in 15-month-old MPS IIIB dogs compared to age-matched
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Animal ID

Phenotype

CSF HS
Age (Months) (pmol/0.6 ul)

67

Unaffected

1

123

Unaffected

1

CSF HS NRE
(pmol/0.6 ul)

CNS HS
(pmol/mg)

CNS HS-NRE
(pmol/mg)

Urine HS
(pmol/nmol
creatinine)
3.06

16.87

Urine HS NRE
(pmol/nmol
Plasma HS
creatinine)
(pmol/0.6 ul)

Plasma
HS-NRE
(pmol/0.6
ul)

0.00

0.00

4.71

0.1

162

Unaffected

2

2.82

0

4.46

0.09

9.10

0.00

163

Unaffected

2

1.16

0

2.12

0.09

10.27

0.00

204

Unaffected

2

2.66

0

0.04

0.01

0.30

58

Unaffected

3

8.58

2.60

104

Unaffected

3

2.18

0

2.47

0.00

7.37

0.02

167

Unaffected

3

1.84

0

10.14

0.00

4.43

0.05

6.50

0.00

168

Unaffected

3

1.94

0

11.19

0.00

3.48

0.13

7.62

0.00

97

Unaffected

9

2.29

0

1.27

0.01

3.77

0.00

2.38

0

100

Unaffected

9

93

Unaffected

12

99

Unaffected

12

434

Unaffected

12

178

MPS IIIB

1

82.09

410

MPS IIIB

1

427

MPS IIIB

376

1.57

0.00

3.70

0.00

1.05

0.00

4.35

0.00

5.58

0.04

3.46

0.00

10.34

0.00

0.76

0.00

2.24

0.00

3.12

84.23

9.87

305.50

7.14

53.81

0.77

91.65

2.36

63.11

17.23

398.03

6.95

37.50

0.42

1

79.16

2.13

90.09

1.49

29.34

0.34

MPS IIIB

2

40.24

1.13

148.46

3.33

38.89

0.40

397

MPS IIIB

2

36.46

0.93

210.00

4.43

37.69

0.45

425

MPS IIIB

2

74.62

2.26

221.79

4.77

38.93

0.54

155

MPS IIIB

3

58.40

9.86

174

MPS IIIB

3

44.25

1.55

133.16

14.79

85.85

1.88

40.63

0.41

179

MPS IIIB

3

58.74

2.22

125.50

13.62

70.85

1.62

33.08

0.43

412

MPS IIIB

3

39.11

1.11

118.97

2.53

44.48

0.39

346

MPS IIIB

6

35.81

0.94

182.17

14.28

147.56

3.36

44.67

0.61

340

MPS IIIB

9

30.02

0.73

37.69

0.38

302

MPS IIIB

12

31.45

0.73

188.53

9.75

326

MPS IIIB

12

35.29

0.76

240.75

14.05

79.95

328

MPS IIIB

12

35.83

0.86

194.16

8.94

33.70

41.93

0.41

1.30

281.37

2.04

0.59

173.61

1.30

Table 1.  Individual animals examined for SensiPro analysis. Individual animal IDs, ages and SensiPro data
collected, including levels of heparan sulfate (HS), heparan sulfate non-reducing ends (HS-NRE) in CNS
tissue, cerebrospinal fluid (CSF), urine and plasma. Blank cells indicate that no data was collected.

Figure 2.  MPS IIIB dogs have increased LAMP1 staining in cortex and white matter. In the area of the cerebral
cortex, 15-month-old MPS IIIB dogs (MPS—grey section) display pronounced LAMP1 immunostaining in two
distinct layers (II/III and VI) that changes into a more pan-laminar (PL) distribution as sections become more
caudal. For each region, the right panel is a macroscopic image whereas the left panel is a 20× magnification.
In MPS IIIB, pronounced white matter (WM) LAMP1 immunostaining within corona radiata (CR) was also
observed, whereas the corpus callosum (CC) contains much less LAMP1 immunostaining. Numbers next to
ages indicate animal ID number.
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Figure 3.  Increased lysosomal storage in hippocampus of MPS IIIB dogs. LAMP1 immunostaining
revealed increased lysosomal storage throughout the hippocampus of 15-month-old MPS IIIB dogs (MPS—
grey background section), including dentate gyrus (DG), CA3 (CA3), and CA1 (CA1). There was also increased
LAMP1 immunostaining in the neurogenic region of the subventricular zone and adjacent white matter.
Numbers next to ages indicate animal ID number.
unaffected dogs (Fig. 2). A dense accumulation of punctate LAMP1 immunoreactivity was present to different
extents in the cytoplasm of individual cells. These cells predominantly had neuronal morphology, although other
smaller cells, presumed to be glia, also contained intense LAMP1 immunoreactivity. This staining of individual
cells also revealed a series of different regional patterns of LAMP1 immunostaining within the forebrain of
15-month-old MPS IIIB dogs.
In the cortex of 15-month-old MPS IIIB dogs, immunostaining for LAMP1 varied in intensity across the
cortical laminae, and at different levels of the brain (Fig. 2). Rostrally, LAMP1 immunostaining was darker within
cells in both superficial (II/III) and deeper laminae (VI), but was less intense in the other laminae. In more caudal regions of cortex, this distinction was less apparent with a more even, pan-laminar staining of cells (Fig. 2).
Within the white matter, there was also a stark contrast in the distribution of LAMP1 staining; the white matter
of the corona radiata that lies directly under cortical grey matter had more intense LAMP1 immunoreactivity
than the adjacent white matter of the corpus callosum, where much less LAMP1 staining was evident.
Hippocampal neurons displayed subfield-specific LAMP1 staining in both unaffected and MPS IIIB dogs.
This immunoreactivity was much darker in pyramidal neurons of CA3 rather than CA1 of MPS IIIB dogs and
also within granule neurons of the dentate gyrus (Fig. 3). There was also staining of LAMP1 with what appeared
to be glia scattered through the hippocampal neuropil of 15-month-old MPS IIIB dogs that was not present in
unaffected control dogs (Fig. 3). MPS IIIB dogs also had markedly more LAMP1 immunoreactivity throughout
the thalamus and hypothalamus, with much more staining within morphologically identified glia, as well as more
numerous large, darkly LAMP1-stained neurons in both structures (Fig. 4). In the hypothalamus, the neurons
in the paraventricular nucleus seemed to have a particularly increased intensity of LAMP1 staining, as did the
nearby substantia nigra. Although unaffected control dogs displayed strong LAMP1 staining in neurons within
the substantia nigra pars compacta, these nigral neurons appeared to be enlarged in MPS IIIB dogs. This morphological appearance is indicative of pronounced storage accumulation, consistent with more intense LAMP1
immunostaining in these affected dogs. In addition, other cell types (likely microglia) were also stained in this
brain region of MPS IIIB dogs. In the thalamus, the dorsolateral geniculate nucleus had robust LAMP1 staining
in both MPS IIIB and unaffected dogs, though staining in neurons of MPS IIIB animals was much darker, as
was background staining of the neuropil.

MPS IIIB dogs do not display cortical atrophy.

Previous data from MPS IIIB mice revealed no evidence of significant cortical a trophy9. Given that mice may not live long enough to develop the full extent of
cortical pathology, we evaluated the presence of cortical atrophy in MPS IIIB dogs by measuring cortical thickness in the most severely affected MPS IIIB dogs ≥ 20 months of age. Measurements were obtained from the
somatosensory cortex, a representative region of the sensory cortex that is most severely affected in large animal
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Figure 4.  Increased lysosomal storage in hypothalamus and thalamus of MPS IIIB dogs. (A) LAMP1
immunostaining reveals pronounced enlargement of the lysosomal compartment in the hypothalamus of
MPS IIIB dogs (MPS—grey background), as revealed by more intense LAMP1 immunoreactivity. LAMP1
immunostaining was increased diffusely throughout the hypothalamus in diseased MPS IIIB animals compared
to unaffected controls. Large, darkly stained neurons were evident in the paraventricular nucleus (PV—1×),
as is evident at higher power (20×). The nearby substantia nigra (SN) of MPS IIIB dogs also contained many
large, darkly LAMP1 immunostained neurons compared to control (20×). (B) The thalamus (Th) of MPS
IIIB dogs generally exhibited darker LAMP1 immunostaining; the dorsolateral geniculate nucleus (dGN)
appeared to contain especially intense immunostaining for this marker. This was largely due to intense LAMP1
immunoreactivity within the neuronal cytoplasm (dGN—20×) but also staining within the neuropil, presumably
within dendritic processes (dGN—20×). Numbers next to ages indicate animal ID number.

models of similar neuropathic lysosomal disorders19. There was no significant difference in the thickness of the
rostral suprasylvian gyrus (Supplementary Figure 3) between this oldest cohort of MPS IIIB dogs and their agematched unaffected counterparts indicating that even in advanced stages of the disease, cortical atrophy does
not occur in this canine MPS IIIB model.

MPS IIIB dogs display qualitative increases in microglial activation in the cerebral cor‑
tex. Despite their lack of overt cortical neurodegeneration, MPS IIIB mice display pronounced and progres-

sive microglial activation9,20. Typical markers of microglial activation, such as CD68, often do not have reactiv-
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Figure 5.  Progressive microglial activation in the cortex of MPS IIIB dogs. Qualitative assessment of
immunostaining for the microglial marker Iba1 revealed differences in the distribution and intensity of
immunoreactivity in both the cortical layers (CL) and white matter (WM) of the cerebral cortex spanning
from 9 to ~ 28 months in the distribution and staining in the cerebral cortex of MPS IIIB dogs (MPS—
grey background). MPS IIIB dogs, in comparison to age-matched unaffected controls (unaffected—
white backgrounds), at early (9 month) and late stages of the disease (28 months) show differences in microglial
morphology and number (magnified inset), and display a larger cell body with thicker processes typical of
activated microglia. An increase in microglial activity in the white matter of diseased MPS IIIB animals was
mainly present in the two oldest cohorts. This difference was especially evident in the white matter adjacent to
the lateral ventricles, including the presence of clusters of activated microglia (see inset). Numbers next to ages
indicate animal ID number.

ity in canine tissue. Instead, immunostaining was performed with Iba1, a microglial marker that is present in
quiescent cells and is increased with microglial activation21. Marked differences in microglial activation and
morphology were observed between unaffected and MPS IIIB dogs. Such changes were evident by 3 months of
age and became more pronounced over time (Fig. 5).
Surveying the distribution of Iba1 immunoreactivity across brain regions of MPS IIIB dogs revealed no particular focal area of microglial activation. For example, within the cortical mantle, Iba1 immunoreactivity was
uniformly increased across the depth of all cortical regions of MPS IIIB dogs, with no greater increase in any
individual lamina (Fig. 5, upper panels). Similar but less pronounced changes were evident within the underlying
white matter (Fig. 5, upper panels). A notable exception was the presence of localized clusters of intensely stained
Iba1-positive microglia in white and grey matter of MPS IIIB dogs of all ages (Fig. 6). Similar microglial clusters
were also observed in unaffected dogs, but to a lesser extent. The distribution of these clusters did not appear to
favor any specific brain region, but occurred with a similar frequency at all rostro-caudal levels of the brain in
both cortical and subcortical structures. Equally, there was no evidence that the clusters associated with blood
vessels and the frequency of the clusters did not appear to correlate with disease progression.
There were also clear differences in microglial morphology between unaffected and MPS IIIB dogs, which
became more pronounced in MPS IIIB dogs with age. In unaffected animals, the many thin ramified Iba1-positive
processes characteristic of quiescent or resting microglia gave the background of the neuropil a “lacy” appearance
(Fig. 5, cortical layer inset), an appearance that was less apparent in MPS IIIB dogs. Morphological changes in
microglia in MPS IIIB dogs reflected their activated state, being not only more intensely stained than cells in unaffected controls, but also with fewer thickened processes and an enlarged cell soma, typical of activated microglia.
Iba1-positive morphologically active microglia were particularly evident in the cortical mantle of MPS IIIB
dogs from 3 months of age and were distributed uniformly throughout the cortex (Fig. 5, and with age morphological differences between Iba1-positive microglia became more pronounced. Twenty-month-old MPS IIIB
dogs had increased incidence of distended microglial cell bodies in the cortical neuropil (Fig. 5). Measurements
of the cross-sectional area of Iba1-positive microglial soma confirmed that these microglia were significantly
larger in MPS IIIB dogs than their wild-type counterparts at 20 months of age or older (Supplemental Figure 2).
There was also a characteristic increase in microglial activation in the white matter in MPS IIIB dogs that was
not seen in unaffected controls (Fig. 5). Although the morphological changes in white matter microglia were
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Figure 6.  MPS IIIB forebrains have more frequent clusters of activated microglia. At all ages, MPS IIIB dogs
(MPS—grey background) had a greatly increased frequency of clusters of intensely Iba1 immunostained
activated microglia. These clusters were especially frequent in the diseased 9- and 15-month-old forebrains.
Also apparent were changes in microglial morphology in MPS IIIB brains, with larger darkly stained microglia
present compared to unaffected brains (see insets). Numbers next to ages indicate animal ID number.

not as pronounced in the cortical grey matter, the soma of these microglia also appeared larger at later stages of
disease progression (Fig. 5, inset).

Cerebellar pathology. The initial characterization of the schipperke dog model of MPS IIIB reported neurologic signs consistent with cerebellar disease, evidence for cerebellar atrophy, and Purkinje neuron loss17. To
broaden these observations, we assessed the degree of storage burden, glial activation, and neuronal survival in
the cerebellum of MPS IIIB dogs.
Increased lysosomal storage in the cerebellum of MPS IIIB dogs. Lysosomal storage burden was
greatly increased in several areas of the cerebellum in the schipperke MPS IIIB dogs17. In our study, immunostaining of LAMP1, a surrogate marker for storage burden, was increased in MPS IIIB dogs at all ages examined, as compared to age-matched unaffected dogs, although there was significant inter-sample variability in
the immunostaining intensity (Fig. 7). In unaffected dogs, LAMP1 staining was very faint, and only appreciable
within the characteristically large soma of Purkinje neurons, whose morphology was readily apparent. In contrast, there was dramatically more LAMP1 staining in MPS IIIB dogs. While this increase was evident at all ages
examined, the difference between the diseased state and unaffected controls was more obvious by 9 months of
age. In these MPS IIIB dogs, LAMP1 not only intensely stained Purkinje neurons and their projections within the
molecular layer, but also stained the granule cell layer and DCN, becoming especially pronounced at 15 months
of age (Fig. 7). In the oldest MPS IIIB dogs, the pattern of LAMP1 staining changed again, with far fewer stained
Purkinje neurons, markedly less staining in the molecular layer, and fewer, more intensely stained cells in the
granule cell layer. This change in distribution could reflect the loss of Purkinje neurons and granule cells in MPS
IIIB dogs, with more LAMP1 staining in microglia (Fig. 7). These findings suggest that storage burden, as measured by LAMP1 immunostaining, reaches a peak in brains of MPS IIIB dogs before tapering off in later stages of
the disease, likely due to cell death of various cell types expressing LAMP1.
Progressive gliosis in the MPS IIIB cerebellum. The activation of both astrocytes and microglia occurs
as a response to cell damage in LSDs such as MPS I IIB9,10,20. Using GFAP as a marker, we assessed the extent of
astrogliosis in canine MPS IIIB disease.
Progressive astrogliosis in the cerebellum of MPS IIIB dogs. Across all age groups, GFAP immu-

nostaining was consistently elevated in MPS IIIB dogs compared to the unaffected controls. However, the high
inter-animal variability precluded quantitative analyses. However, even unaffected animals at all ages displayed
a substantial number of GFAP-positive Bergman glia within most folia, although these cells displayed relatively
thin processes (Fig. 8, Bergman glia). This was accompanied in unaffected dogs by relatively little staining of
fibrous astrocytes within the cerebellar white matter (Fig. 8, white matter). In contrast, the pattern and intensity of GFAP immunostaining was markedly different in MPS IIIB dogs at all ages examined (Fig. 8, grey), and
became more complex with disease progression. Bergman glia in MPS IIIB dogs displayed much thicker processes than in corresponding age-matched unaffected controls (Fig. 8), and a distinctive band of GFAP immunostaining was evident at the interface between granule and molecular layers, marking where Purkinje cells
normally sit (Fig. 8, Purkinje layer). This reached its peak intensity in MPS IIIB dogs by 15 months of age, before
declining in older MPS IIIB dogs (Fig. 8). This was accompanied by progressively more GFAP immunostaining
with increased age within both the granule cell layer, and perhaps most notably within the white matter and
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Figure 7.  Enlargement of the lysosomal compartment in the cerebellum of MPS IIIB dogs. (A) Immunostaining for
the lysosomal marker LAMP1 provides a surrogate marker for storage material accumulation and reveals a progressive
increase in the size of the lysosome in the cerebellum of MPS IIIB dogs (MPS IIIB—grey) compared to unaffected controls
(unaffected—white). These changes, examined using thresholding analysis, were apparent in the molecular layer, the Purkinje
cell layer, the cerebellar white matter and the deep cerebellar nuclei (DCN). (B–E) Thresholding image analysis of LAMP1
immunostaining confirms the progressive increase in staining intensity for this marker in the cerebellum of MPS IIIB dogs
compared to unaffected controls. Markedly increased LAMP1 staining was evident in all regions except the white matter (D)
by 15 months of age, and in all regions by later stages (~ 28 months). Error bars indicate SEM. Number of animals analyzed (3
mo: unaffected n = 2, MPS IIIB n = 2; 9 mo: unaffected n = 2, MPS IIIB n = 2; 15 mo: unaffected n = 2, MPS IIIB n = 3; > 20 mo:
unaffected n = 2, MPS IIIB n = 3). Numbers next to ages indicate animal ID number.
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Figure 8.  Astrocytosis in the MPS IIIB dog cerebellum. Qualitative assessment of immunostaining for the
astrocyte marker GFAP reveal progressive changes from 9 to ~ 28 months in the distribution and staining
intensity in the different layers of the cerebellum of MPS IIIB dogs (MPS—grey background). Comparison of
MPS IIIB animals to unaffected controls (unaffected—white background) at early (9 month) and late stages of
the disease (28 months) shows qualitative differences particularly in the white matter and deep cerebellar nuclei,
primarily at later stages. Abbreviations: bg, Bergmann glia layer; pl, Purkinje layer; wm, white matter. Numbers
next to ages indicate animal ID number.

DCN of MPS IIIB dogs (Fig. 8). Increased GFAP immunostaining within the white matter was already visible in
MPS IIIB dogs from 9 months of age, revealing a distinctive outlining of astrocyte processes around blood vessels within the cerebellar white matter (Fig. 8). These results suggest progressive changes in astrocyte activation
in MPS IIIB dogs, specifically around the Purkinje cell layer and cerebellar white matter.

Microgliosis is most prominent in the DCN in cerebellum of MPS IIIB dogs. Iba1 immunoreactivity was much less variable than GFAP staining and revealed changes in morphology and increased Iba1
immunostaining in MPS IIIB dogs compared to the unaffected controls from 9 months of age, and were more
pronounced at later stages (Fig. 9). Compared to the lacy appearance of the neuropil in unaffected dogs, Iba1positive microglia in MPS IIIB dogs displayed fewer, thicker processes and had enlarged cell soma. A distinctive
appearance of very large microglia and/or clusters of intensely stained Iba1-positive cells were seen sporadically
within both granule and molecular layers of MPS IIIB dogs from 9 months of age. Compared to astrocytosis,
microglial activation was less pronounced within the white matter of MPS IIIB dogs, but was still markedly
higher than in unaffected dogs, with localised activation evident in the DCN (Fig. 9). Quantification of Iba1
immunoreactivity via thresholding image analysis revealed some inter-animal variability. In particular, one of
the 9-month-old MPS IIIB brains had markedly increased Iba1 immunostaining than any other brain of the
same age. However, there was a significant increase in Iba1 immunoreactivity in white matter of MPS IIIB dogs
at > 20 months of age (Fig. 9D), with a trend starting at 15 months of age. A similar trend in relative Iba1 immunoreactivity was seen in the DCN of MPS IIIB dogs, but not in their cerebellar cortices in either the molecular
or granular layers. These results indicate, similarly to the atrophy, much of the cerebellar microgliosis occurs in
the white matter. While there were obvious changes in microglial morphology in the cerebellar cortical layers
of MPS IIIB dogs, significant changes in Iba1 immunoreactivity were detected only in the white matter and the
DCN.
Loss of neurons and white matter atrophy in the cerebellum of MPS IIIB dogs. Purkinje cells
and neurons in the DCN provide the major efferent output from the cerebellum, indicating their importance
for cerebellar functions. Loss of these cells was analyzed by Nissl staining and the sections were used to evaluate white matter volume loss and cerebellar cortical thickness (Fig. 10). The thickness of cerebellar molecular
and granular layers was measured in the posterior lobe of the cerebellum both separately and together, but
revealed no significant change in the thickness of any cerebellar cortical layer in MPS IIIB dogs at any age (data
not shown). Cerebellar white matter volume changes were apparent in MPS IIIB dogs from 15 months of age,
but became statistically significant at > 20 months of age when the volume was decreased by more than 50%
(Fig. 10A). There was an increase in white matter volume in unaffected dogs over time, potentially due to ongoing myelination during postnatal maturation, which was not evident in MPS IIIB dogs, resulted in a significantly
smaller volume in the oldest MPS IIIB dogs (Fig. 10A). A marked decrease in Purkinje cells (15–20%) was
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Figure 9.  Microglial activation in the MPS IIIB dog cerebellum. (A) Immunostaining for the microglial marker
Iba1 revealed progressive changes from 9 to ~ 28 months in the distribution and staining in the cerebellum of
MPS IIIB dogs (MPS—grey background). MPS IIIB animals, in comparison to unaffected controls (unaffected—
white background) at early (9 month) and late stages of the disease (28 months) shows differences in microglial
morphology and number, displaying a larger cell body with thicker processes, typical of activated microglia. (BE) Quantification using thresholding image analysis of Iba1 immunostaining confirms the progressive increase
in immunostaining intensity in the cerebellum of MPS IIIB dogs compared to unaffected controls (unaffected).
Pronounced trends towards increases in Iba1 immunostaining appear in all regions but are significant in the
cerebellar white matter (D) and deep cerebellar nuclei (E) (*p < 0.05). Abbreviations: ml, molecular layer; gl,
granular layer; wm, white matter. Error bars indicate SEM. Number of animals analyzed (3 mo: unaffected
n = 2, MPS IIIB n = 2; 9 mo: unaffected n = 2, MPS IIIB n = 2; 15 mo: unaffected n = 2, MPS IIIB n = 3; > 20 mo:
unaffected n = 2, MPS IIIB n = 3). Numbers next to ages indicate animal ID number.
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Figure 10.  Progressive neuron loss in the cerebellum of MPS IIIB dogs. Statistical significance between
unaffected and MPS IIIB dogs is indicated by ** (0.01) and *** (0.001). (A) MPS IIIB dogs did not display the
progressive increase in white matter volume seen in unaffected dogs, resulting in reduced white matter volume
in late stage MPS IIIB dogs. (B) Purkinje cell counts revealed progressive loss in MPS IIIB dogs. (C) Unbiased
stereological counts revealed progressive loss of neurons in the deep cerebellar nuclei (DCN) of MPS IIIB
dogs; neuron numbers at 15 and > 20 months of age were significantly decreased compared to those found in
unaffected dogs. Examining just the data from MPS IIIB dogs (grey bars) revealed a significant decrease in DCN
neurons at 9, 15, and 28 months compared to 3 months of age. Error bars indicate SEM. Number of animals
analyzed (3 mo: unaffected n = 2, MPS IIIB n = 2; 9 mo: unaffected n = 2, MPS IIIB n = 2; 15 mo: unaffected n = 2,
MPS IIIB n = 3; > 20 mo: unaffected n = 2, MPS IIIB n = 3). Numbers next to ages indicate animal ID number.

observed in the posterior lobe of the cerebellum of MPS IIIB dogs at all ages when compared to age-matched
unaffected controls. Though this did not reach statistical significance, the trend in Purkinje cell loss with disease
progression was evident (Fig. 10B). Optical fractionator counts of Nissl-stained DCN neurons showed a pronounced loss of these cells in MPS IIIB dogs by 9 months of age, which then remained stable at later stages of
disease (Fig. 10C). Compared to unaffected controls, the loss of DCN neurons in MPS IIIB dogs became statistically significant after 15 months of age. However, compared to 3- month-old MPS IIIB dogs, the loss of DCN
neurons was statistically significant from 9 months onwards (Fig. 10C). Taken together, these data indicate that
cerebellar atrophy occurs primarily in the white matter, and that there is progressive loss of DCN neurons that
has not been reported previously.

Discussion

In this study, we assessed the development of disease pathology in the canine model of MPS IIIB before they
display any signs, by evaluating biochemical and histopathological measures of lysosomal storage accumulation,
neurodegeneration, and atrophy.
The changes in levels of both HS and MPS IIIB-specific HS-NRE were evaluated in cortical grey matter, CSF,
plasma, and urine from MPS IIIB dogs. Even by 1 month of age, HS and HS-NRE levels in tissues and body fluids
from MPS IIIB dogs were higher than the levels in the corresponding samples from unaffected dogs. However,
the kinetics of HS and HS-NRE accumulation differ across the four tissues or body fluids. While levels of HS and
HS-NRE in cortical grey matter of MPS IIIB dogs increase over time, levels of HS and HS-NRE in CSF and urine
of MPS IIIB dogs were higher at 1 month of age than at subsequent time points. Despite this early decrease, levels
of HS and HS-NRE in CSF and urine of MPS IIIB dogs at these later time points remain elevated in comparison
to the levels present in unaffected dogs of any time point. High levels of urinary GAGs have been reported previously in healthy newborn humans and have been suggested to be associated with increased turnover of extracellular matrix during d
 evelopment22–24. Elevated levels of HS and HS-NRE in the CSF and urine of 1-month old
MPS IIIB dogs could be indicative of the ongoing brain growth and increased turnover of extracellular matrix that
occurs during this time period25. Further studies that include additional WT and MPS IIIB dogs at younger ages
will be needed to fully understand the mechanism driving the early elevated levels of HS and HS-NRE in MPS
IIIB dogs. Any future studies of potential therapies that initiate prior to HS and HS-NRE levels reaching steady
state in the CSF of MPS IIIB dogs will need to distinguish between the developmentally associated decrease in
HS levels, and that due to any therapeutic benefit at these early time points.
Disease-related pathology illustrated by increased intensity of LAMP1 immunostaining was observed in
multiple brain regions of preclinical MPS IIIB dogs and was accompanied by a progressive increase in microgliosis (cortex and cerebellum) and astrogliosis (cerebellum). The distribution of these changes is similar to that
of histological changes seen in the brain of an MPS IIB patient26, suggesting that the dog model recapitulates
this aspect of the human disease.
Pathological evaluation of the cerebellum confirmed it to be the most severely affected brain region in preclinical MPS IIIB dogs, displaying neuropathological changes that are evident relatively early in disease progression. One of the most prominent and previously unreported findings within the cerebellum was a substantial 50%
loss of DCN neurons. This loss occurred relatively early in disease progression (present by 9 months of age) and
did not appear to progress further, indicating that the majority of DCN neurodegeneration occurs in early stages
of the disease. As such, it may be important to look in patients for symptoms that could potentially be related to
this DCN loss. There was also significant cerebellar white matter atrophy in preclinical MPS IIIB dogs, which had
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almost half the volume compared to unaffected dogs. This may be due to axon loss or a demyelination process
resulting from a degeneration or dysfunction of oligodendrocytes or defective myelination during post-natal
development. However, we observed an increase in white matter volume in unaffected dogs suggestive of ongoing myelination during this time in development. The degree of Purkinje cell loss in these MPS IIIB dog samples
was relatively small and not significantly different from controls, as was previously reported in older a nimals17.
Quantitative analysis revealed clear signs of increased storage burden in cerebellar cortical layers of MPS IIIB
dogs in addition to DCN and cerebellar white matter. Taken together these observations indicate that the DCN
are the primary pathological target within the MPS IIIB cerebellum, exhibiting pronounced neurodegeneration
and atrophy of surrounding white matter tissue.
The time-dependent accumulation of HS in the forebrain and progressive increase in LAMP1 staining in both
the forebrain and cerebellum in MPS IIIB dogs indicate that MPS IIIB disease pathology clearly occurs prior
to the onset of clinical signs in animals. Such signs only occur subsequent to 20 months of age, with all but the
most severely affected dogs examined in this study being younger than this. While disease-related pathology
is present throughout the brain, the cerebellum is more dramatically affected than other regions in preclinical
MPS IIIB dogs. Although the loss of Purkinje neurons has been documented previously in the schipperke MPS
IIIB dogs17, our current findings provide the first evidence for pronounced pathology within deeper structures
of the cerebellum that include the white matter and DCN.
While human MPS IIIB disease is thought to primarily affect cortical brain regions, the extent to which the
cerebellum is affected and plays a role in the disease symptoms has not been thoroughly investigated. Interestingly, early stage MPS IIIB disease shares many symptoms with autism despite the different etiologies and MPS
IIIB is often misdiagnosed as a utism27. Similar symptoms include motor dysfunction, aggressiveness, hyperactivity, and language and communication deficits27. In addition to changes in brainstem volume and cortical
regions, autism is associated with cerebellar atrophy and dysfunction, which may cause motor dysfunction as
well as some non-motor symptoms such as deficits in language, communication, social interactions, stereotyped
behavior, and cognitive dysfunction28,29. Similar symptoms are observed in MPS IIIB patients, suggesting that the
cerebellar pathology seen in the MPS IIIB dogs may have relevance for early stages of human MPS IIIB disease.
Later stages of the human MPS IIIB disease, which ultimately result in a vegetative state, are likely to involve
more widespread neurodegeneration.
Our study reveals the dynamics of the onset and progression of neuropathology in this large animal model of
MPS IIIB disease, before the onset of disease signs. We describe a series of markers that can be used for assessing
therapeutic benefit in future studies, focusing on well-defined neuropathological and biochemical endpoints
including the direct measure of NAGLU substrate accumulation (HS and HS-NRE), Iba1 as a marker of microglial activation, and LAMP1 as a marker of lysosomal enlargement.

Materials and methods

Dogs and tissue extraction. The outbred MPS IIIB canine colony was founded based on a naturallyoccurring mutation in schipperke dogs17. Animals were genotyped by 7 days old with polymerase chain reaction at the canine NAGLU locus, and enzyme deficiency was confirmed by testing their serum enzyme levels30.
The MPS IIIB dogs and their unaffected counterparts were produced and maintained at Iowa State University’s
Department of Animal Science according to guidelines of the USDA and NIH, and under approved protocols
of the ISU IACUC. Animals were kept with their dams until weaning, and at 4 months segregated by sex. After
weaning, dogs were fed ad libitum. CSF was aseptically collected under full anaesthesia by puncture of the
cisterna magna after which dogs were euthanized by intravenous administration of sodium pentobarbital at
approximately 1, 2, 3, 6, 9, 12, 15, and 20 months of age, after which encephalectomy was performed by Iowa
State University Department of Animal Science staff. The numbers of individual dogs analysed at each age is
summarized in Table 1 (SensiPro) and Table 2 (histology). Brains were cut sagittally into hemispheres at the
level of the longitudinal fissure, with one half immersion fixed in 10% neutral buffered formalin and the other
half frozen and stored at − 80 °C. Tissue samples for HS analysis were derived from frozen hemispheres, which
were placed at − 20 °C overnight, with tissue samples dissected directly from these − 20 °C frozen brains. Cortical
grey matter was taken from the medial aspect of the precruciate gyrus. Urine and blood samples were collected
pre-mortem (serum) or immediately post-mortem (urine).
Quantification of total and disease‑specific heparan sulfate. Total HS and MPS IIIB-specific HSNRE in homogenized brain tissue (cerebral grey matter), CSF, serum and urine from approximately 1, 2, 3, 6,
9, and 12-month-old unaffected or MPS IIIB dogs (exact ages of dogs for whom brain tissue, CSF, plasma, and
urine were analyzed varied by sample availability) were quantified using the HS-NRE liquid chromatographymass spectrometry (LCMS) assay (SensiPro) as described previously2,10,31. Briefly, HS from the samples was
purified by anion exchange chromatography and digested with heparan lyases (IBEX Technologies). The HS
fragments were tagged with isotropically labelled aniline by reductive amination and quantified by LCMS. Total
HS (internal disaccharides) and the MPS IIIB-specific HS-NRE (N-acetylglucosamine-2-sulfated iduronic acidN-sulfated glucosamine [GlcNAc-IdoA2S-GlcNS], referred to as A0I2S0) are expressed as pmol/mg brain wet
weight, pmol/0.6 μl CSF or plasma, or pmol/nmol creatinine in urine.
Histological preparation of brain tissue. Brains were stored in formalin for extended periods before

histology was performed. Before beginning histology, brain hemispheres were submerged in cryoprotectant,
30% sucrose in Tris-buffered saline (TBS: 50 mM Tris, 150 mM NaCl, pH 7.6) for at least two weeks. The forebrain was then separated from the cerebellum and cut perpendicular to the long axis of the brain into three
rostrocaudal blocks that were sectioned individually. Blocks were coated with Lipshaw M-1 cryomatrix resin
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IBA1
ID

Phenotype

Age (months)

670

MPS IIIB

676

MPS IIIB

LAMP1

WM

ML

GL

3

0.4

3.8

3.6

3

1.8

10.2

DCN

WM

ML

4.0

2.2338

1.1984

GL
0.0810

DCN
0.1509

1.0

0.7

2.3489

4.1601

0.1048

0.1681

340

MPS IIIB

9

20.2

42.3

60.1

20.7

0.2562

1.5429

0.1434

1.9971

292

MPS IIIB

9

6.2

8.1

9.2

5.4

0.0022

0.0094

0.0000

0.0002

302

MPS IIIB

15

5.1

6.8

8.7

10.7

1.2043

0.0007

10.7174

24.9239

326

MPS IIIB

16.6

9.0

10.3

9.4

25.8

0.3975

0.0003

0.4723

12.3951

328

MPS IIIB

16.6

227

MPS IIIB

25

6.0

6.2

5.6

13.9

0.5270

0.0001

0.3418

2.0102

11.1

14.0

10.2

9.7

6.4790

1.5660

7.9240

34.7327

200

MPS IIIB

28

12.0

11.5

11.3

15.0

0.1783

0.0004

0.1189

2.5216

197

MPS IIIB

28

14.8

15.3

19.9

24.9

0.0003

0.0005

0.0094

0.2200

674

Unaffected

3

0.2

2.9

0.2

1.7

4.8459

0.2378

4.4699

0.2684

675

Unaffected

3

0.5

2.4

0.4

0.9

0.8453

5.2396

1.7916

4.1729

208

Unaffected

9

2.2

8.2

8.9

2.1

0.0006

0.0011

0.0002

0.0002

210

Unaffected

9

4.8

14.0

12.6

4.2

0.0000

0.0078

0.0023

0.0000

93

Unaffected

15

4.4

9.8

9.2

2.6

0.0000

0.0009

0.0001

0.0006

99

Unaffected

15

5.1

7.7

7.9

1.9

0.0003

0.0000

0.0012

0.0021

132

Unaffected

22

7.2

8.9

9.2

4.5

0.0004

0.0000

0.0092

0.1325

323

Unaffected

22

5.3

11.3

10.2

2.0

0.0019

0.0000

0.0043

0.0400

Table 2.  Individual animals examined for histological analysis. Individual animal IDs, ages and thresholding
image analysis data collected from the cerebellum for the microglial marker IBA1 and for lysosomal membrane
associated protein 1 (LAMP1). Regions measured include cerebellar white matter (WM), molecular layer
(ML), granule cell layer (GL) and deep cerebellar nucleus (DCN).

(ThermoFisher Scientific, Leicestershire, UK) and the forebrain cut coronally on a freezing microtome at 50 µm
(Microm HM430, ThermoFisher Scientific), with the cerebellum cut sagittally. Sections were collected into 24
well plates containing a lab-derived cryoprotectant solution (TBS containing 30% ethylene glycol, 15% sucrose,
and 0.05% sodium azide), and stored at 4 °C until staining was performed.

Nissl staining. In order to visualize tissue cytoarchitecture, regularly spaced sections were Nissl stained

with cresyl violet, as described p
 reviously32. Briefly, every forty-eighth 50 µm section through each block was
mounted onto microscope slides previously double coated with gelatin-chrome allum (ThermoFisher Scientific).
After air drying for at least 24 h, sections were incubated in 0.025% cresyl violet (Merck, Darmstadt, Germany)
and 0.05% acetic acid (VWR, Dorset, UK) at 56 °C for 30 min. Sections were then differentiated through a series
of graded concentrations of industrial methylated spirits (IMS, VWR) and cleared in xylene (VWR) for at least
24 h before coverslipping with DPX (VWR), a xylene-based mountant.

Immunohistochemical staining. To assess lysosomal storage and microglial activation in the forebrain

and cerebellum, regularly spaced sections were selected, and immunohistochemically stained, using standard
protocols33, for the markers LAMP1 (lysosomal membrane protein 1, lysosomes) and Iba1 (ionized calcium
binding adaptor molecule 1, a calcium binding protein specific to microglia and macrophages), in addition to
GFAP (glial fibrillary associated protein, astrocyte activation) in the cerebellum. Briefly, after quenching endogenous peroxidase activity in 1% H
 2O2 (Fisher Scientific) for 25 min, sections were rinsed, and to reduce nonspecific protein binding were incubated with 15% normal serum (serum from the host species of the secondary
antibody) in TBS-T (TBS containing 0.3% IBA/v Triton X-100) for 30 min. Primary antibody was applied in a
10% serum solution in TBS-T (Polyclonal goat anti-Iba1, 1:1000; polyclonal rabbit anti-LAMP1, 1:500, Abcam,
Cambridge, UK; polyclonal rabbit anti-GFAP, 1:2000, Dako Ltd, Ely, UK), and left to incubate overnight at room
temperature. After rinsing, sections were incubated with secondary antiserum (rabbit anti goat for Iba1, 1:1000;
Vector; swine anti-rabbit for LAMP1 & GFAP; Dako, Cambridgeshire, UK) in TBS-T with 10% normal swine or
rabbit serum, respectively, for 2 h. After rinsing with TBS, sections were incubated overnight with avidin–biotinperoxidase complex (Vectastatin Elite ABC kit, Vector Laboratories, 1:1000). To visualize immunoreactivity,
slides were incubated in a 0.05% solution of 3, 3′- diaminobenzidine tetrahydrochloride (DAB; Sigma, Dorset,
UK) with 0.001% H
 2O2 solution in TBS for approximately 8 min. The reaction was stopped with ice-cold TBS.
After rinsing with TBS, sections were mounted on Superfrost Plus microscope slides (ThermoFisher Scientific),
and air dried overnight. Slides were then cleared with xylene, and coverslipped with DPX (VWR).

Cortical thickness. To assess potential differences in cortical thickness, Nissl-stained sections were meas-

ured perpendicularly from the pial surface to white matter border, and this thickness was analyzed with StereoInvestigator software (MBF Bioscience Inc., Williston, VT, USA). These measurements were made in the primary
somatosensory cortex, the rostral suprasylvian gyrus; this region was identified according to neuroanatomical
landmarks34. Three sections containing this region were selected from each brain, and slides were blinded to age
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and treatment before analysis started. Ten measurements of cortical thickness were made per section, and these
measurements were made in areas as far from gyrus curvature as possible to minimize variability. The mean
regional cortical thickness was then calculated for each brain.

Stereological counts of neuron number.

Optical fractionator counts of the number of Nissl-stained
DCN neurons were made using an appropriate grid size and dissector frame. Only neurons with a clearly identified morphology that fell within the dissector frame were counted. For all optical fractionator estimates, the
mean coefficient of error of individual estimates was calculated according to the method of Gundersen and
Jensen35 and was less than 0.08 in all these analyses. The number of Purkinje neurons was counted manually and
expressed as the number per unit length within the same folium in each brain.

Measurements of microglial area. The mean size of Iba1-stained microglia in the forebrain was obtained
by measuring the cross-sectional area of at least 100 morphologically identified Iba1-stained microglia in each
animal using StereoInvestigator software, and the mean microglial area determined ± standard area of the mean
(SEM).
Thresholding image analysis. The expression of GFAP, Iba1, and LAMP1 was measured in the cerebel-

lum by semi-quantitative image thresholding analysis of each antigen. From three consecutive immunostained
sections, 10 non-overlapping images were captured from each section for each of the areas examined. All images
were captured at 40X objective by a live video camera (JVC, 3CCD, KY-F55B) mounted on Zeiss Axioplan
universal microscope (Germany). The lamp intensity, video camera setup, and calibration were kept constant
throughout the image capturing process. Image-Pro Plus 5.0 software (MediaCybernetics, Chicago, IL, USA) was
used to analyze the images with an appropriate threshold selected to distinguish the foreground immunostaining
above the background. Macros were recorded to transfer the data to a spreadsheet for statistical analysis. The
data obtained from the thresholding analysis was plotted graphically as a mean percentage area of immunoreactivity per treatment group ± SEM.

Statistical analysis. All statistical analyses were performed blinded to genotype and age, which was only
revealed once all morphological analyses were completed. A Kolmogorov–Smirnov test, a nonparametric test
which assesses the empirical distribution functions of two samples, was applied to measured microglial cell body
areas (GraphPad Prism, La Jolla, CA). A t-test was used to determine whether there was a statistically significant
difference between genotype groups in cortical thickness of somatosensory cortex. Results were considered statistically significant if they produced a p value less than or equal to 0.05.

Data availability

The data sets analyzed in this study are available from the corresponding author upon reasonable request.
Received: 15 January 2020; Accepted: 13 October 2020
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